F. Pouya, Yousef Rasmi, M. Nemati
{"title":"New insights into the effects of hydroxychloroquine in COVID-19","authors":"F. Pouya, Yousef Rasmi, M. Nemati","doi":"10.22034/HBB.2021.13","DOIUrl":null,"url":null,"abstract":"In late 2019 until 2021, the novel coronavirus disease (COVID-19) has become pandemic. This disease is related to severe inflammatory symptoms of the respiratory epithelial cells and the dysfunction of several organs. One of the suggested drugs to reduce the inflammation caused by COVID-19 is hydroxychloroquine. Studies have shown this drug blocks the inflammatory pathway of nuclear factor-κB by blocking P21 activated kinase 1. Also, nanoparticle vaccines Poly Lactide-Glycolide) Acid (PLGA) containing hydroxychloroquine are effective in cancer by stimulating CD8T + cells responses. This study assumed that hydroxychloroquine was effective in inhibiting COVID-19 with these mechanisms. © 2021 Health Biotechnology And Biopharma. All Rights Reserved.","PeriodicalId":288173,"journal":{"name":"Health Biotechnology and Biopharma","volume":"85 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Biotechnology and Biopharma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22034/HBB.2021.13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
羟氯喹治疗COVID-19的新见解
2019年底至2021年,新型冠状病毒病(COVID-19)已成为大流行。本病与呼吸道上皮细胞的严重炎症症状和多个器官功能障碍有关。羟氯喹是减少COVID-19引起的炎症的建议药物之一。研究表明,该药通过阻断P21活化激酶1阻断核因子-κB炎症通路。此外,含有羟氯喹的纳米颗粒疫苗聚乳酸-乙醇酸(PLGA)通过刺激CD8T +细胞反应而对癌症有效。本研究假设羟氯喹通过这些机制有效抑制COVID-19。©2021健康生物技术和生物制药。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。